Dr Rozenblit on Pembrolizumab Outcomes by TMB Status in HR+ Metastatic Breast Cancer

Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine, discusses findings from a study evaluating the prevalence of actionable genomic alterations and the predictive value of tumor mutational burden (TMB) for the efficacy of immune checkpoint inhibitors in patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

Videos

Mariya Rozenblit, MD, discusses how genomic alterations and TMB influence the efficacy of immune checkpoint inhibitors in HR+ metastatic breast cancer.

Mariya Rozenblit, MD

Articles

Dr Rozenblit on Pembrolizumab Outcomes by TMB Status in HR+ Metastatic Breast Cancer